Chronic Hepatitis BExposure to Adefovir Dipivoxil

Total

2084

ADV 10 mg

1647

Other ADV doses

437

Phase 2, Supportive Studies, Early Access

831

Pivotal studies and

transplantation

816

? 48 Weeks

578

? 72 Weeks

420

? 96 Weeks

256

As of NDA Safety update

Previous slide

Next slide

Back to first slide

View graphic version